Search details
1.
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma.
Future Oncol
; 19(40): 2623-2629, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37526095
2.
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Prostate
; 82(13): 1237-1247, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35675470
3.
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
J Urol
; 205(5): 1361-1371, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33356529
4.
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Int J Urol
; 28(7): 765-773, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33955599
5.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Oncologist
; 24(9): 1151-e817, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31171735
6.
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Future Oncol
; 15(11): 1219-1230, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30701988
7.
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.
Future Oncol
; 15(1): 53-63, 2019 Jan.
Article
in English
| MEDLINE | ID: mdl-30058839
8.
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
Future Oncol
; 15(17): 1997-2007, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-31084373
9.
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Lancet Oncol
; 19(3): 405-415, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29439857
10.
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Neuroendocrinology
; 107(3): 237-245, 2018.
Article
in English
| MEDLINE | ID: mdl-29991024
11.
12.
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Lancet Oncol
; 14(13): 1287-94, 2013 Dec.
Article
in English
| MEDLINE | ID: mdl-24206640
13.
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Lancet Oncol
; 14(6): 552-62, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23598172
14.
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Cancer
; 119(14): 2555-63, 2013 07 15.
Article
in English
| MEDLINE | ID: mdl-23605883
15.
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Eur Urol Oncol
; 2023 Dec 09.
Article
in English
| MEDLINE | ID: mdl-38072761
16.
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Eur Urol
; 84(2): 229-241, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37179240
17.
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet
; 378(9807): 1931-9, 2011 Dec 03.
Article
in English
| MEDLINE | ID: mdl-22056247
18.
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
J Clin Oncol
; 40(15): 1616-1622, 2022 05 20.
Article
in English
| MEDLINE | ID: mdl-35420921
19.
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Prostate Cancer Prostatic Dis
; 25(2): 274-282, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34420037
20.
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
Target Oncol
; 16(1): 27-35, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33411058